Krystal Biotech Reiterated FY24 R&D And SG&A Expense Of $150M-$175M
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech has reiterated its financial guidance for FY24, expecting Non-GAAP R&D and SG&A expenses to be between $150 million and $175 million. This guidance does not include stock-based compensation due to its inherent uncertainty.
August 05, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Krystal Biotech has reiterated its FY24 financial guidance, expecting Non-GAAP R&D and SG&A expenses to be between $150 million and $175 million. The exclusion of stock-based compensation introduces some uncertainty.
The reiteration of financial guidance provides stability and predictability for investors, but the exclusion of stock-based compensation introduces some uncertainty. This is likely to have a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100